Cargando…

Treatment of Immunocompromised, Critically Ill Patients with Influenza A H1N1 Infection with a Combination of Oseltamivir, Amantadine, and Zanamivir

Immunocompromised patients are at increased risk of complications of influenza virus infection. We report on two critically ill patients on immunosuppressive medication with influenza pneumonia. In both patients, oseltamivir monotherapy did not result in clearance of the virus after 18 and five days...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meijer, Wouter J., Kromdijk, Wiete, van den Broek, Marcel P. H., Haas, Pieter-Jan A., Minnema, Monique C., Boucher, Charles A., de Lange, Dylan W., Wensing, Annemarie M. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546743/ https://www.ncbi.nlm.nih.gov/pubmed/26346659 http://dx.doi.org/10.1155/2015/504975

Ejemplares similares

Oseltamivir-Resistant Pandemic (H1N1) 2009 Treated with Nebulized Zanamivir
por: Da Dalt, Liviana, et al.
Publicado: (2010)

Comparison of efficacy and safety of oseltamivir and zanamivir in pandemic influenza treatment
por: Tuna, Nazan, et al.
Publicado: (2012)

Oseltamivir- and Amantadine-Resistant Influenza Virus A (H1N1)
por: Cheng, Peter K.C., et al.
Publicado: (2010)

Oseltamivir- and Amantadine-Resistant Influenza Viruses A (H1N1)
por: Cheng, Peter K.C., et al.
Publicado: (2009)

A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir
por: Matsuzaki, Yoko, et al.
Publicado: (2010)

Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014
por: Trebbien, Ramona, et al.
Publicado: (2017)

Why are oseltamivir and zanamivir effective against the newly emerged influenza A virus (A/H1N1)?
por: Yu, Kunqian, et al.
Publicado: (2009)

Oseltamivir/zanamivir: Lack of efficacy leading to fatal influenza A (H1N1) infection: case report
Publicado: (2013)

A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir
por: Abed, Yacine, et al.
Publicado: (2017)

Efficacy of Combined Therapy with Amantadine, Oseltamivir, and Ribavirin In Vivo against Susceptible and Amantadine-Resistant Influenza A Viruses
por: Nguyen, Jack T., et al.
Publicado: (2012)

Simultaneous Detection of Oseltamivir- and Amantadine-Resistant Influenza by Oligonucleotide Microarray Visualization
por: Zhang, Yingjie, et al.
Publicado: (2013)

IF-03 Clinical Effectiveness of Oseltamivir or Zanamivir for Influenza A/H1N1 Virus with or without H274Y Mutation
por: Kawai, Naoki, et al.
Publicado: (2009)

Study of Oseltamivir and Zanamivir Resistance-Related Mutations in Influenza Viruses Isolated from Wild Mallards in Sweden
por: Orozovic, Goran, et al.
Publicado: (2014)

Pharmacokinetics of oseltamivir carboxylate in critically ill patients: each patient is unique
por: Kromdijk, W., et al.
Publicado: (2013)

Detection of Resistance Mutations to Antivirals Oseltamivir and Zanamivir in Avian Influenza A Viruses Isolated from Wild Birds
por: Orozovic, Goran, et al.
Publicado: (2011)

Efficacy of Oseltamivir-Zanamivir Combination Compared to Each Monotherapy for Seasonal Influenza: A Randomized Placebo-Controlled Trial
por: Duval, Xavier, et al.
Publicado: (2010)

Efficacy of oseltamivir compared with zanamivir in COPD patients with seasonal influenza virus infection: a randomized controlled trial
por: Li, Min, et al.
Publicado: (2020)

A Randomized, Crossover Study to Evaluate the Pharmacokinetics of Amantadine and Oseltamivir Administered Alone and in Combination
por: Morrison, Dennis, et al.
Publicado: (2007)

Correction: Efficacy of Oseltamivir-Zanamivir Combination Compared to Each Monotherapy for Seasonal Influenza: A Randomized Placebo-Controlled Trial
por: Duval, Xavier, et al.
Publicado: (2010)

Oseltamivir‐resistant influenza A 2009 H1N1 virus in immunocompromised patients
por: Couturier, Brianne A., et al.
Publicado: (2010)

Zanamivir should be inhaled, not nebulised
por: Eagel, Barry A
Publicado: (2010)

I223R Mutation in Influenza A(H1N1)pdm09 Neuraminidase Confers Reduced Susceptibility to Oseltamivir and Zanamivir and Enhanced Resistance with H275Y
por: LeGoff, Jérome, et al.
Publicado: (2012)

Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: a randomized, double-blind, placebo-controlled safety trial over 16 weeks
por: Anekthananon, T., et al.
Publicado: (2013)

Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: a randomized, double-blind, placebo-controlled safety trial over 16 weeks
por: Anekthananon, T., et al.
Publicado: (2013)

Triple Combination of Amantadine, Ribavirin, and Oseltamivir Is Highly Active and Synergistic against Drug Resistant Influenza Virus Strains In Vitro
por: Nguyen, Jack T., et al.
Publicado: (2010)

Different Inhibitory Potencies of Oseltamivir Carboxylate, Zanamivir, and Several Tannins on Bacterial and Viral Neuraminidases as Assessed in a Cell-Free Fluorescence-Based Enzyme Inhibition Assay
por: Quosdorf, Stefanie, et al.
Publicado: (2017)

Triple Combination Antiviral Drug (TCAD) Composed of Amantadine, Oseltamivir, and Ribavirin Impedes the Selection of Drug-Resistant Influenza A Virus
por: Hoopes, Justin D., et al.
Publicado: (2011)

Intravenous zanamivir for influenza myocarditis and enteral malabsorption
por: Jahns, Fritz-Patrick, et al.
Publicado: (2018)

Progressive emergence of an oseltamivir‐resistant A(H3N2) virus over two courses of oseltamivir treatment in an immunocompromised paediatric patient
por: Hurt, Aeron C., et al.
Publicado: (2013)

Influenza A(H1N1) Oseltamivir Resistant Viruses in the Netherlands During the Winter 2007/2008
por: Dijkstra, Frederika, et al.
Publicado: (2011)

Neuraminidase Inhibitor Zanamivir Ameliorates Collagen-Induced Arthritis
por: Sehnert, Bettina, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Conventional-Dose vs Triple-Dose Oseltamivir in Severely Immunocompromised Children With Influenza
por: Bautista, Francisco, et al.
Publicado: (2019)

Intrahost emergent dynamics of oseltamivir-resistant virus of pandemic influenza A (H1N1) 2009 in a fatally immunocompromised patient
por: Hamada, Nobuyuki, et al.
Publicado: (2012)

Structural analysis of the novel influenza A (H7N9) viral Neuraminidase interactions with current approved neuraminidase inhibitors Oseltamivir, Zanamivir, and Peramivir in the presence of mutation R289K
por: Tran-To Su, Chinh, et al.
Publicado: (2013)

Zanamivir Oral Delivery: Enhanced Plasma and Lung Bioavailability in Rats
por: Shanmugam, Srinivasan, et al.
Publicado: (2013)

Lessons from resistance analysis in clinical trials of IV zanamivir
por: Yates, Phillip J, et al.
Publicado: (2023)

High Rate of Chronic Villitis in Placentas of Pregnancies Complicated by Influenza A/H1N1 Infection
por: Meijer, Wouter J., et al.
Publicado: (2014)

Effects of amantadine on circulating neurotransmitters in healthy subjects
por: Lechin, Fuad, et al.
Publicado: (2010)

Evaluation of the Antiviral Response to Zanamivir Administered Intravenously for Treatment of Critically Ill Patients With Pandemic Influenza A (H1N1) Infection
por: Fraaij, P. L. A., et al.
Publicado: (2011)

Zanamivir for the prevention of influenza in adults and children age 5 years and older
por: Eiland, Lea S, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_pgpaknns81vmarcjetnev1noti